Kalaitzakis and Björnsson DeVault KR, Castell DO. 2005. Updated guidelines for the diagnosis and treatment of gastroesophageal reﬂux disease. Am J Gastroenterol, 100:190–200. Devault KR, Johanson JF, Johnson DA, et al. 2006. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole ﬁfteen milligrams. Clin Gastroenterol Hepatol, 4:852–9. Edwards SJ, Lind T, Lundell L. 2001. Systematic review of proton pump inhibitors for the acute treatment of reﬂux oesophagitis. Aliment Pharmacol Ther, 15:1729–36. Edwards SJ, Lind T, Lundell L. 2006. Systematic review: proton pump inhibitors PPIs. for the healing of reﬂux oesophagitis – a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther, 24:743–50. Fennerty MB, Johanson JF, Hwang C, et al. 2005. Efﬁcacy of esomeprazole 40 mg vs lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther, 21:455–63. Fock KM, Teo EK, Ang TL, et al. 2005. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reﬂux disease: a randomized, double- blind study in urban Asia. World J Gastroenterol, 11:3091–8. Frazzoni M, De Micheli E, Savarino V. 2003. Different patterns of oesophageal acid exposure distinguish complicated reﬂux disease from either erosive reﬂux oesophagitis or non-erosive reﬂux disease. Aliment Pharmacol Ther, 18:1091–8. Frazzoni M, Manno M, De Micheli E, et al. 2006. Intra-oesophageal acid suppression in complicated gastro-oesophageal reﬂux disease: esomeprazole versus lansoprazole. Dig Liver Dis, 38:85–90. Gillessen A, Beil W, Modlin IM, et al. 2004. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reﬂux disease-related symptoms. J Clin Gastroenterol, 38:332–40. Gralnek IM, Dulai GS, Fennerty MB, et al. 2006. Esomeprazole Versus Other Proton Pump Inhibitors in Erosive Esophagitis: A Meta- Analysis of Randomized Clinical Trials. Clin Gastroenterol Hepatol, 4:1452–8. Hansen AN, Bergheim R, Fagertun H, et al. 2006. Long-term management of patients with symptoms of gastro-oesophageal reﬂux disease – a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract, 60:15–22. Hatlebakk JG. 2003. Review article: gastric acidity – comparison of esome- prazole with other proton pump inhibitors. Aliment Pharmacol Ther, 17(Suppl 1):10–15; discussion 16–17. Hellstrom PM, Vitols S. 2004. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol, 94:106–11. Holtmann G, Cain C, Malfertheiner P. 1999. Gastric Helicobacter pylori infection accelerates healing of reﬂux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology, 117:11–16. Howden CW, Ballard ED II, Robieson W. 2002. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole in the treatment of erosive esophagitis. Clin Drug Investig, 22:99–109. Hunt RH. 1999. Importance of pH control in the management of GERD. Arch Intern Med, 159, 649–57. Johansson KE, Ask P, Boeryd B, et al. 1986. Oesophagitis, signs of reﬂux, and gastric acid secretion in patients with symptoms of gastro- oesophageal reﬂux disease. Scand J Gastroenterol, 21:837–47. Johnson DA, Benjamin SB, Vakil NB, et al. 2001. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reﬂux disease symp- toms: a randomized, double-blind, placebo-controlled study of efﬁcacy and safety. Am J Gastroenterol, 96:27–34. Johnson DA, Stacy T, Ryan M, et al. 2005. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reﬂux disease. Aliment Pharmacol Ther, 22:129–34. 662 Johnsson F, Joelsson B, Gudmundsson K, et al. 1987. Symptoms and endoscopic ﬁndings in the diagnosis of gastroesophageal reﬂux disease. Scand J Gastroenterol, 22:714–18. Kahrilas PJ, Falk GW, Johnson DA, et al. 2000. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reﬂux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther, 14:1249–58. Katz PO, Castell DO, Chen Y, et al. 2004. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three- way crossover study. Aliment Pharmacol Ther, 20:399–406. Kendall MJ. 2003. Review article: Esomeprazole – the ﬁrst proton pump inhibitor to be developed as an isomer. Aliment Pharmacol Ther, 17(Suppl 1):1–4. Klok RM, Postma MJ, van Hout BA, et al. 2003. Meta-analysis: comparing the efﬁcacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther, 17:1237–45. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. 2004. Cure of Helico- bacter pylori infection in patients with reﬂux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reﬂux disease: results of a randomised controlled trial. Gut, 53:12–20. Kulig M, Leodolter A, Vieth M, et al. 2003. Quality of life in relation to symptoms in patients with gastro-oesophageal reﬂux disease – an analysis based on the ProGERD initiative. Aliment Pharmacol Ther, 18:767–76. Labenz J, Armstrong D, Lauritsen K, et al. 2005a. Esomeprazole 20 mg vs pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther, 22:803–11. Labenz J, Armstrong D, Lauritsen K, et al. 2005b. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther, 21:739–46. Labenz J, Tillenburg B, Peitz U, et al. 1996. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology, 110:725–32. Lauritsen K, Deviere J, Bigard MA, et al. 2003. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reﬂux oesophagitis: Metropole study results. Aliment Pharmacol Ther, 17:333–41. Lind T, Havelund T, Carlsson R, et al. 1997. Heartburn without oesophagitis: efﬁcacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol, 32:974–9. Lind T, Rydberg L, Kyleback A, et al. 2000. Esomeprazole provides improved acid control vs omeprazole In patients with symptoms of gastro- oesophageal reﬂux disease. Aliment Pharmacol Ther, 14:861–7. Martinez SD, Malagon IB, Garewal HS, et al. 2003. Non-erosive reﬂux disease NERD – acid reﬂux and symptom patterns. Aliment Pharmacol Ther, 17:537–45. Miehlke S, Madisch A, Kirsch C, et al. 2005. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily – a randomized, two-way crossover study. Aliment Phar- macol Ther, 21:963–7. Miner P Jr, Katz PO, Chen Y, et al. 2003. Gastric acid control with esome- prazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a ﬁve-way crossover study. Am J Gastroenterol, 98:2616–20. Moayyedi P, Talley NJ. 2006. Gastro-oesophageal reﬂux disease. Lancet, 367:2086–100. Monnikes H, Pfaffenberger B, Gatz G, et al. 2005. Novel measurement of rapid treatment success with ReQuest: ﬁrst and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion, 71:152–8. Pace F, Negrini C, Wiklund I, et al. 2005. Quality of life in acute and main- tenance treatment of non-erosive and mild erosive gastro-oesophageal reﬂux disease. Aliment Pharmacol Ther, 22:349–56. Prasad M, Rentz AM, Revicki DA. 2003. The impact of treatment for gastro-oesophageal reﬂux disease on health-related quality of life: a literature review. Pharmacoeconomics, 21:769–90. Therapeutics and Clinical Risk Management 2007:3(4)